Publication:
Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype

dc.contributor.authorvon Massow, Georg
dc.contributor.authorGarcia-Cehic, Damir
dc.contributor.authorGregori, Josep
dc.contributor.authorRodriguez-Frias, Francisco
dc.contributor.authorDolores Macia, Maria
dc.contributor.authorEscarda Gelabert, Ana
dc.contributor.authorIgnacio Esteban, Juan
dc.contributor.authorQuer, Josep
dc.date.accessioned2024-09-10T13:07:01Z
dc.date.available2024-09-10T13:07:01Z
dc.date.issued2019
dc.description.abstractHepatitis C virus (HCV) is a highly variable infectious agent, classified into 8 genotypes and 86 subtypes. Our laboratory has implemented an in-house developed high-resolution HCV subtyping method based on next-generation sequencing (NGS) for error-free classification of the virus using phylogenetic analysis and analysis of genetic distances in sequences from patient samples compared to reference sequences. During routine diagnostic, a sample from an Equatorial Guinea patient could not be classified into any of the existing subtypes. The whole genome was analyzed to confirm that the new isolate could be classified as a new HCV subtype. In addition, naturally occurring resistance-associated substitutions (RAS) were analyzed by NGS. Whole-genome analysis based on p-distances suggests that the sample belongs to a new HCV genotype 1 subtype. Several RAS in the NS3 (S122T, D168E and I170V) and NS5A protein (Q(1b)24K, R(1b)30Q and Y93L+Y93F) were found, which could limit the use of some inhibitors for treating this subtype. RAS studies of new subtypes are of great interest for tailoring treatment, as no data on treatment efficacy are reported. In our case, the patient has not yet been treated, and the RAS report will be used to design the most effective treatment.en
dc.description.sponsorshipThis study was supported by the Spanish Ministry of Health, Consumption and Social Welfare grant name Plan Estrategico Nacional contra la Hepatitis C. This study was funded by Instituto de Salud Carlos III grants, PI15/00856, PI15/00829 and PI16/00337, and cofinanced by CIBERehd (Consorcio Centro de Investigacion en Red de Enfermedades Hepaticas y Digestivas), which is funded by Instituto de Salud Carlos III and Centro para el Desarrollo Tecnologico Industrial-CDTI from the Spanish Ministry of Economy and Business, grant number, IDI-20151125.es_ES
dc.format.page947-955es_ES
dc.format.volume12es_ES
dc.identifier.citationVon Massow G, Garcia-Cehic D, Gregori J, Rodriguez-Frias F, Macia Romero MD, Escarda A, et al. Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype. Infect Drug Resistance. 2019;12:947-55.en
dc.identifier.doi10.2147/IDR.S195441
dc.identifier.issn1178-6973
dc.identifier.journalInfection and Drug Resistancees_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/17154
dc.identifier.pubmedID31118701es_ES
dc.identifier.puiL2001904227
dc.identifier.scopus2-s2.0-85066992952
dc.identifier.urihttps://hdl.handle.net/20.500.12105/22679
dc.identifier.wos467090600001
dc.language.isoengen
dc.publisherDove Medical Press
dc.relation.publisherversionhttps://dx.doi.org/10.2147/IDR.S195441en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution-NonCommercial 3.0 Unported*
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/*
dc.subjectSubtype
dc.subjectDirect-acting antivirals
dc.subjectHCV
dc.subjectGenotype 1
dc.titleWhole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtypeen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublicationba22643b-836b-4738-8dc3-444eb4bd4ec4
relation.isPublisherOfPublication.latestForDiscoveryba22643b-836b-4738-8dc3-444eb4bd4ec4

Files